MiR-338 targets oncogenes such as RAB32 and EYA2, and its downregulation in cancer is also linked to overexpression of epidermal growth factor receptor (EGFR)41,42 and MET transcriptional regulator (MACC1)43. Here, EGFR is linked to cancer.